Want to join the conversation?
$EMR 3Q15 PR: Net sales were $5,503MM, down 13% vs. $6,312MM in 3Q14. Underlying sales were down 5% excluding unfavorable currency translation of 5% and an impact from divestitures of 3%. Net earnings were $564MM or $0.84 per diluted share vs. $728MM or $1.03 per diluted share in 3Q14.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)